UK markets closed
  • NIKKEI 225

    29,100.38
    -584.99 (-1.97%)
     
  • HANG SENG

    29,135.73
    +29.58 (+0.10%)
     
  • CRUDE OIL

    62.55
    -0.83 (-1.31%)
     
  • GOLD FUTURES

    1,778.60
    +8.00 (+0.45%)
     
  • DOW

    33,771.14
    -306.49 (-0.90%)
     
  • BTC-GBP

    40,069.89
    +452.50 (+1.14%)
     
  • CMC Crypto 200

    1,270.59
    +36.17 (+2.93%)
     
  • ^IXIC

    13,758.84
    -155.92 (-1.12%)
     
  • ^FTAS

    3,920.05
    -76.60 (-1.92%)
     

Immatics Announces Full Year 2020 Financial Results and Corporate Update

  • Oops!
    Something went wrong.
    Please try again later.
Immatics N.V.
·14-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Phase 1a data update from clinical ACTengine® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients

  • Enrollment across clinical ACTengine® IMA200 trial series continues to scale up

  • Cash and cash equivalents as well as other financial assets of $285 million1 (€232 million) as of December 31, 2020 provide cash reach into 2023

Tuebingen, Germany and Houston, TX, March 30, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2020.

Harpreet Singh, Ph.D., CEO of Immatics commented, “The past year was exceptional for Immatics with the advancement of our pipeline programs, expansion of our leadership team and scientific advisory board and the completion of our listing on the Nasdaq. Building on this foundation, we have recently delivered encouraging data from three clinical TCR-T studies demonstrating first anti-tumor activity in heavily pre-treated solid cancer patients. This early data also constitutes a first clinical validation for our differentiated TCR therapeutics platform. We look forward to reporting further data from our Phase 1 ACTengine® TCR-T trials as well as the progress in our TCR Bispecifics programs (TCER®) in the latter part of this year.”

Fourth Quarter 2020 and Subsequent Company Progress

Adoptive Cell Therapy Programs

  • ACTengine® IMA200 series - Immatics provided a clinical data update from three ongoing ACTengine® Phase 1 trials for its engineered Adoptive Cell Therapy approach (also known as TCR-T) in March. The combined data readout during early phases of dose escalation for the ACTengine® programs, IMA201, IMA202 and IMA203, indicated first anti-tumor activity with tumor shrinkage observed in 8 out of 10 patients including one unconfirmed partial response as of data cut-off. This was consistent with the observed robust engraftment, persistence and tumor infiltration of infused ACTengine® T cells. Overall, all product candidates demonstrated a manageable safety and tolerability profile. An additional Phase 1a read-out for IMA201 and IMA203 and initial Phase 1b data for IMA202 from the dose expansion cohort is planned for H2 2021. Submission of a clinical trial application (CTA) for the fourth IMA200 series program, IMA204, remains anticipated for H2 2021. The company presented the first preclinical data for the program in September 2020, which is directed at a novel target, COL6A3 exon 6 that is expressed in the tumor stroma of a variety of solid cancers.


TCR Bispecifics Programs

  • IMA401 – Immatics presented preclinical proof-of-concept data from its lead TCER® program, IMA401, at the European Antibody Congress 2020 in November. IMA401 is an antibody-like, “off-the-shelf” biologic directed against a high-density peptide target derived from MAGEA4/8. Submission of a CTA for IMA401 remains on track by the end of 2021.

  • IMA402 – Immatics plans to announce preclinical proof-of-concept data for its second TCER® program, IMA402 in Q2 2021. GMP process development activities are targeted to begin at the same time to advance this program towards the Investigational New Drug (IND) stage and clinical development.

Corporate Developments

Scientific Advisory Board Update

  • Immatics has established a new Scientific Advisory Board (SAB) comprised of several leaders and scientific pioneers in immuno-oncology, adoptive cell therapies, clinical oncology and cancer biology. The members of the new SAB include Gwendolyn Binder, Dirk Busch, Christoph Huber, Patrick Hwu, Roland Kontermann, Crystal Mackall, Hidde Ploegh, Hans-Georg Rammensee, and Cassian Yee. Patrick Hwu and Crystal Mackall will co-chair the SAB. Additional information about the members can be found on the Immatics website.

Amendment to Resale Registration Statement

  • In connection with the filing of the Annual Report on Form 20-F, Immatics will file an amendment to its existing resale registration statement on Form F-1 to update certain information. This registration statement relates solely to the resale of shares by certain stockholders, and the filing of the amendment is not necessarily indicative of any sales by the holders of their shares. No shares will be issued or sold by Immatics pursuant to the registration statement.

Full Year 2020 Financial Results

Cash Position: Cash and cash equivalents as well as other financial assets total €232.0 million ($284.7 million1) as of December 31, 2020 compared to €119.4 million ($146.5 million1) as of December 31, 2019. The increase is mainly the result of the business combination with ARYA Sciences Acquisition Corporation completed in July 2020 (ARYA merger) and the concurrent PIPE Financing.

Revenue: Total revenue, consisting of revenue from collaboration agreements, was €31.3 million ($38.4 million1) for the year ended December 31, 2020, compared to €18.4 million ($22.6 million1) for the year ended December 31, 2019.

Research and Development Expenses: R&D expenses were €67.1 million ($82.3 million1) for the year ended December 31, 2020, compared to €40.1 million ($49.2 million1) for the year ended December 31, 2019. The increase is mainly due to an increase in preclinical and clinical development expenses and an increase in share-based compensation (€14.5 million; $17.8 million1 for the year ended December 31, 2020 compared to €1.6 million; $1.9 million for the year ended December 31, 2019).

General and Administrative Expenses: G&A expenses were €34.2 million ($42.0 million1) for the year ended December 31, 2020, compared to €11.8 million ($14.5 million1) for the year ended December 31, 2019. The increase is mainly due to an increase in share-based compensation (€10.9 million; $13.4 million1 for the year ended December 31, 2020 compared to €0.5 million; $0.6 million for the year ended December 31, 2019) as well as one-time transaction costs of the NASDAQ listing in connection with the ARYA merger in July.

Net Loss: Net loss was €229.6 million ($281.7 million1) for the year ended December 31, 2020, compared to €32.5 million ($39.9 million1) for the year ended December 31, 2019, of which €152.8 million ($187.5 million1) resulted from a one-time, non-cash expense in connection with the ARYA merger. The main part of this €152.8 million ($187.5 million1) non-cash expense resulted from the share price increase between signing and closing of the ARYA merger.

Full financial statements can be found in the Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) and published on the SEC website under www.sec.gov.

1 All amounts translated using the exchange rate published by the European Central Bank in effect as of December 31, 2020 (1 EUR = 1.2271 USD).

Upcoming Investor Conferences

  • Kempen Life Science – April 28, 2021

  • Bank of America Healthcare Conference – May 11-13, 2021

  • Jefferies Virtual Healthcare Conference – June 1-3, 2021


To see the full list of events and presentations, visit www.investors.immatics.com/events-presentations.

About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on Twitter and LinkedIn.

Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics’ future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics’ focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the SEC. Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.

For more information, please contact:

For Media Inquiries

Investor Relations Contact

Jacob Verghese or Stephanie May

John Graziano

Trophic Communications

Solebury Trout

Phone: +49 89 2388 7731

Phone: +1 646 378 2942

immatics@trophic.eu

jgraziano@soleburytrout.com


Immatics N.V.

Anja Heuer

Jordan Silverstein

Corporate Communications

Head of Strategy

Phone: +49 89 540415-606

Phone: +1 281 810 7545

media@immatics.com

InvestorRelations@immatics.com


Immatics N.V. and subsidiaries

Condensed Consolidated Statement of Financial Position of Immatics N.V.



As of

December 31, 2020

December 31, 2019

(Euros in thousands)

Assets

Current assets

Cash and cash equivalents

207,530

103,353

Other financial assets

24,448

16,023

Accounts receivable

1,250

957

Other current assets

5,763

3,667

Total current assets

238,991

124,000

Non-current assets

Property, plant and equipment

7,868

4,720

Intangible assets

914

1,008

Right-of-use assets

6,149

3,287

Other non-current assets

724

1,262

Total non-current assets

15,655

10,277

Total assets

254,646

134,277

Liabilities and shareholders' deficit

Current liabilities

Provisions

51

50

Accounts payable

10,052

7,082

Deferred revenue

46,600

59,465

Lease liabilities

1,881

1,411

Other current liabilities

2,025

1,288

Total current liabilities

60,609

69,296

Non-current liabilities

Deferred revenue

85,475

101,909

Lease liabilities

4,306

1,823

Other non-current liabilities

-

2,084

Total non-current liabilities

89,781

105,816

Shareholders' equity (deficit)

Share capital

629

1,164

Share premium

573,339

190,945

Accumulated deficit

(462,253)

(233,194)

Other reserves

(7,459)

(770)

Total equity (deficit) attributable to shareholders of the parent

104,256

(41,855)

Non-controlling interest

-

1,020

Total shareholders' equity (deficit)

104,256

(40,835)

Total liabilities and shareholders' equity (deficit)

254,646

134,277


Immatics N.V. and subsidiaries

Condensed Consolidated Statement of Loss of Immatics N.V.

Year ended December 31,

2020

2019

2018

(Euros in thousands, except share and per share data)

Revenue from collaboration agreements

31,253

18,449

3,770

Research and development expenses

(67,085)

(40,091)

(33,971)

General and administrative expenses

(34,186)

(11,756)

(7,666)

Other income

303

385

3,458

Operating result

(69,715)

(33,013)

(34,409)

Financial income

2,949

790

2,215

Financial expenses

(10,063)

(264)

(161)

Share listing expense

(152,787)

-

-

Financial result

(159,901)

526

2,054

Loss before taxes

(229,616)

(32,487)

(32,355)

Taxes on income

-

-

-

Net loss

(229,616)

(32,487)

(32,355)

Attributable to:

Equity holders of the parent

(229,059)

(31,571)

(31,444)

Non-controlling interest

(557)

(916)

(911)

Net loss

(229,616)

(32,487)

(32,355)

Net loss per share - basic and diluted

(4.77)

(0.95)

(0.95)

Weighted average shares outstanding - basic and diluted

48,001,228

33,093,838

33,093,838



Immatics N.V. and subsidiaries

Condensed Consolidated Statement of Comprehensive Loss of Immatics N.V.

Year ended December 31,

Notes

2020

2019

2018

(Euros in thousands)

Net Loss

(229,616)

(32,487)

(32,355)

Other comprehensive loss

Items that may be reclassified subsequently to profit or loss, net of tax

-

-

-

Currency translation differences from foreign operations

(6,689)

(29)

313

Total comprehensive loss for the period

(236,305)

(32,516)

(32,042)

Attributable to:

Equity holders of the parent

(235,748)

(31,600)

(31,131)

Non-controlling interest

20

(557)

(916)

(911)

Total comprehensive loss for the period

(236,305)

(32,516)

(32,042)

Immatics N.V. and subsidiaries

Condensed Consolidated Statement of Cash Flows of Immatics N.V.

Year ended December 31,

2020

2019

2018

(Euros in thousands)

Cash flows from operating activities

Loss before taxation

(229,616)

(32,487)

(32,355)

Adjustments for:

Interest income

(850)

(790)

(507)

Depreciation and amortization

4,424

3,858

2,176

Interest expense

289

170

16

Share listing expense

152,787

-

-

Equity settled share-based payment

22,908

152

118

MD Anderson compensation expense

45

700

1,360

(Decrease) Increase in other liabilities resulting from share appreciation rights

(2,036)

1,864

220

Payment related to share-based compensation awards previously classified as equity-settled

(4,322)

-

-

Net foreign exchange differences

(4,477)

3

-

Changes in working capital

Increase in accounts receivable

(294)

(563)

(175)

Increase in other assets

(1,600)

(1,497)

5,608

(Increase) decrease in accounts payable and other current liabilities

(23,387)

98,937

43,732

Interest received

808

790

507

Interest paid

(289)

(170)

(16)

Net cash provided by/(used in) operating activities

(85,610)

70,967

20,684

Cash flows from investing activities

Payments for property, plant and equipment

(7,420)

(2,143)

(429)

Cash paid for investments in Other financial assets

(82,930)

(20,473)

(13,101)

Cash received from maturity of investments classified in Other financial assets

74,505

17,551

-

Payments for intangible assets

(104)

(91)

(78)

Proceeds from disposal of property, plant and equipment

-

97

94

Net cash provided by/(used in) investing activities

(15,949)

(5,059)

(13,514)

Cash flows from financing activities

Proceeds from issuance of shares to equity holders of the parent

217,918

-

23,648

Transaction cost deducted from equity

(7,939)

Payments for leases

(2,096)

(1,862)

-

Net cash provided by/(used in) financing activities

207,883

(1,862)

23,648

Net increase in cash and cash equivalents

106,324

64,046

30,818

Cash and cash equivalents at beginning of period

103,353

39,367

8,415

Effects of exchange rate changes on cash and cash equivalents

(2,147)

(60)

134

Cash and cash equivalents at end of period

207,530

103,353

39,367


Immatics N.V. and subsidiaries

Condensed Consolidated Statement of Changes in Shareholders’ equity (deficit) of Immatics N.V.

(Euros in thousands)

Notes

Share capital

Share premium

Accumulated deficit

Other reserves

Total equity attributable to shareholders of the parent

Non-controlling interest

Total share-holders' equity (deficit)

Balance as of January 1, 2018

1,164

167,027

(170,179)

(1,054)

(3,042)

787

(2,255)

Other comprehensive loss

-

-

-

313

313

-

313

Net loss

-

-

(31,444)

-

(31,444)

(911)

(32,355)

Comprehensive loss for the year

-

-

(31,444)

313

(31,131)

(911)

(32,042)

Equity-settled tandem awards

18

-

118

-

-

118

-

118

Issuance of ordinary shares

19

-

23,648

-

-

23,648

-

23,648

MD Anderson compensation expense

20

-

-

-

-

-

1,360

1,360

Balance as of December 31, 2018

1,164

190,793

(201,623)

(741)

(10,407)

1,236

(9,171)

Balance as of January 1, 2019

1,164

190,793

(201,623)

(741)

(10,407)

1,236

(9,171)

Other comprehensive loss

-

-

-

(29)

(29)

-

(29)

Net loss

-

-

(31,571)

-

(31,571)

(916)

(32,487)

Comprehensive loss for the year

-

-

(31,571)

(29)

(31,600)

(916)

(32,516)

Equity-settled tandem awards

18

-

152

-

-

152

-

152

MD Anderson compensation expense

20

-

-

-

-

-

700

700

Balance as of December 31, 2019

1,164

190,945

(233,194)

(770)

(41,855)

1,020

(40,835)

Balance as of January 1, 2020

1,164

190,945

(233,194)

(770)

(41,855)

1,020

(40,835)

Other comprehensive loss

-

-

-

(6,689)

(6,689)

-

(6,689)

Net loss

-

-

(229,059)

-

(229,059)

(557)

(229,616)

Comprehensive loss for the year

-

-

(229,059)

(6,689)

(235,748)

(557)

(236,305)

Reorganization

3,19

(833)

833

-

-

-

-

-

Issue of share capital

MD Anderson Share Exchange

3,19

7

501

-

-

508

(508)

-

PIPE Financing, net of transaction costs

3, 19

104

89,973

-

-

90,077

-

90,077

ARYA Merger, net of transaction costs

3,19, 17

180

272,508

-

-

272,688

-

272,688

SAR conversion

18

7

(7)

-

-

-

-

-

Total issuance of share capital

298

362,975

-

-

363,273

(508)

362,765

Equity-settled share-based compensation

18

-

22,908

-

-

22,908

-

22,908

Payment related to share-based compensation awards previously classified as equity-settled

18

-

(4,322)

-

-

(4,322)

-

(4,322)

MD Anderson compensation expense

20

-

-

-

-

-

45

45

Balance as of December 31, 2020

629

573,339

(462,253)

(7,459)

104,256

-

104,256



Attachment